Data on the safety of inclisiran, a lipid-lowering small interfering RNA (siRNA) inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) secretion, during pregnancy are absent. CASE SUMMARY. A 30-year-old woman suffering from heterozygous familial hypercholesterolaemia...
Moreover, inclisiran sodium 300 mg (The Medicines Company) administered twice yearly was well tolerated and safe, with an adverse event profile similar to treatment with placebo,Kausik K. Ray, MD, MPhil,from the Imperial Center for Cardiovascular Dise...
inclisiran was administered subcutaneously at dose levels of 10, 50, and 250 mg/kg every 2 weeks for 4 weeks before cohabitation through mating, and until termination between Days 64 and 67. In female rats, inclisiran was administered subcutaneously at dose levels of 10, 50...